Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
AssigneeWisconsin Alumni Research Foundation
InventorsHector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism and/or to treat and/or prevent the symptoms of primary hyperparathyroidism in as subject having or at risk for developing primary hyperparathyroidism, preferably without inducing hypercalcemia in the patient.
Claims8
A method of reducing serum parathyroid hormone levels in a subject having primary hyperparathyroidism and exhibiting elevated serum parathyroid hormone levels, the method comprising administering a therapeutically effective amount of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 or a pharmaceutically acceptable salt thereof to the subject wherein the serum parathyroid hormone levels in the subject are reduced without inducing hypercalcemia in the subject.
Dependencies are inferred from the claim text.